Acadia Pharmaceuticals

Acadia Pharmaceuticals

ACAD· Manufacturing· Fiscal year ends in December

No proxy on file names the CEO of Acadia Pharmaceuticals.

Executives9

See all
  1. 1Thomas GarnerFY2023
  2. 2Catherine OwenNot disclosed
  3. 3Catherine Owen AdamsNot disclosed
  4. 4Elizabeth ThompsonNot disclosed
  5. 5Jennifer RhodesNot disclosed
  6. 6Mark C. SchneyerNot disclosed

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Acadia Pharmaceuticals paid its one named executive on file $0 in FY2023 (Dec).

Name
Thomas GarnerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers19

See all

The FY2024 (Dec) proxy of Acadia Pharmaceuticals names 19 peer companies for pay. Among Acadia Pharmaceuticals and these peers, CEO pay was 7th highest of 9 and total shareholder return was the lowest of 9.

7th highest of 9in Acadia Pharmaceuticals and its pay peers, FY2024 (Dec) by CEO pay:

$2.0M$17.8M

9th highest of 9in Acadia Pharmaceuticals and its pay peers, FY2024 (Dec) by total shareholder return:

$43$289

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board5

See all
  • Laura A. BregeDirector · 17 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
  • Edmund P. HarriganDirector · 10 yr on the boardIndependentAudit—Paid as an executive
  • Julian C. BakerDirector · 10 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • James M. DalyDirector · 9 yr on the boardIndependentAudit, Compensation—Paid as an executive
  • Elizabeth A. GarofaloDirector · 5 yr on the boardIndependentCompensation—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

Filings6

See all
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 28, 2024FY2023